+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 26 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are studying the long-term safety and tolerability of JNJ-81201887, given as an injection into the eye, for people with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD. This extension study follows participants who took part in earlier parent studies to continue monitoring their health without new treatments given during this phase. The study aims to understand how participants respond over an extended period after the initial treatment. Participants who previously received either a low or high dose of JNJ-81201887, or a sham procedure, in earlier clinical trials will join this long-term extension study. No additional treatments or interventions will be provided during this study. The trial is designed to observe participants without administering further study drugs, focusing on those who were part of the parent studies identified by specific study codes. Throughout the study, participants will be monitored for up to 5 years. Assessments will include checking for any eye-related or systemic side effects, abnormalities in laboratory tests, retinal imaging, and eye examinations. Visual acuity changes will also be measured from baseline up to 42 months. Participants will provide informed consent and be regularly evaluated to track their health and visual function over time.

Age: 60Years +All GendersPhase 2Phase 3
104 locations
R

Actively Recruiting

Researchers are studying ALN-5288, an investigational drug given intrathecally, in adults aged 40 to 80 years who have Alzheimers Disease, including mild cognitive impairment or dementia due to AD. This Phase 1 trial aims to evaluate the safety and tolerability of ALN-5288 and to understand how the drug behaves and affects the body through pharmacodynamic and pharmacokinetic measurements. Participants will be randomly assigned to receive either ALN-5288 or placebo during a double-blind period, followed by an open-label extension where all participants receive ALN-5288. Both ALN-5288 and placebo are administered intrathecally, which involves delivery into the spinal canal. The study is designed to monitor participants for up to 32 months. During the study, participants will undergo various assessments including monitoring for adverse events, measuring concentrations of ALN-5288 and total Tau protein in cerebrospinal fluid, plasma, and urine over time. Safety evaluations will include physical exams, blood pressure measurements, ECGs, and laboratory tests. The study involves long-term follow-up to assess the drugs effects and safety throughout the treatment period.

Age: 40Years - 80YearsAll GendersPhase 1
13 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of Hetrombopag Olamine Tablets compared to a placebo in patients with thrombocytopenia caused by chemotherapy. The study focuses on patients who have solid tumors and experience low platelet counts due to chemotherapy treatment. This phase III trial is conducted by Jiangsu HengRui Medicine Co., Ltd. and aims to better understand treatment options for chemotherapy-induced thrombocytopenia. Participants receive treatments in two parts in Part A, all participants are given Hetrombopag Olamine. In Part B, participants are randomly assigned to receive either Hetrombopag Olamine or a matching placebo. Treatments are given during chemotherapy cycles that occur every 14 or 21 days. The study includes monitoring over approximately 3 years to assess platelet counts and the need for rescue therapies. During the study, participants undergo regular monitoring of platelet levels, safety labs, and vital signs. Researchers track whether participants maintain platelet counts sufficient to continue chemotherapy without delay or modification. Outcomes include measuring platelet count improvements, bleeding events, and adverse reactions. The overall participation lasts up to about three years, with ongoing assessment of chemotherapy cycle completion and treatment safety.

Age: 18Years +All GendersPhase 3
51 locations
E

Actively Recruiting

Researchers are studying the effects of prasinezumab, given as an intravenous infusion, in people aged 50 to 85 with early-stage Parkinsons disease who are already receiving stable levodopa treatment. The study aims to compare prasinezumab to a placebo to evaluate its safety, how the body processes the drug, and its impact on motor symptoms related to Parkinsons disease. Participants will be randomly assigned to receive either prasinezumab or a placebo through IV infusions during the double-blind treatment phase. After this phase, eligible participants can join an open-label extension where they receive prasinezumab. The study follows participants for at least 104 weeks, with infusions and assessments scheduled throughout this period. During the study, participants will have regular visits for motor function assessments using the Movement Disorder Society Unified Parkinsons Disease Rating Scale MDS-UPDRS and other measures. Researchers will monitor adverse events, infusion reactions, and the presence of antibodies against prasinezumab. Blood samples will be taken at multiple time points to measure drug levels and immune responses. The total study duration extends through 2031, including safety follow-up after the last dose.

Age: 50Years - 85YearsAll GendersPhase 3
192 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the combination of KarXT and KarX-EC for cognitive impairment in people with mild to moderate Alzheimers Disease. This phase 3, randomized, double-blind, placebo-controlled study aims to understand how these treatments impact cognitive function and overall condition in this patient group. Participants will be randomly assigned to receive either KarXT plus KarX-EC or a placebo, with specified doses given on specific days. The treatment period lasts 24 weeks, during which participants will be monitored closely to assess changes in cognition and daily functioning. Throughout the 24 weeks, participants will undergo evaluations including cognitive tests like the Alzheimers Disease Assessment Scale-Cognitive Subscale 11 and the Clinicians Interview-Based Impression plus Caregiver Input. Researchers will also track safety through monitoring adverse events, vital signs, lab tests, and other clinical assessments to understand the treatments impact and safety profile.

Age: 60Years - 85YearsAll GendersPhase 3
119 locations
A

Actively Recruiting

Researchers are investigating whether using artificial intelligence AI to guide monitoring and timing of ovulation trigger in women undergoing ovarian stimulation for in vitro fertilization IVF can achieve clinical outcomes similar to traditional physician-led decisions. This trial aims to compare AI-assisted decision-making with routine clinical management to optimize the number of eggs retrieved, improve workflow efficiency, and reduce clinical workload, especially weekend procedures. Participants will be randomly assigned to one of two groups one where trigger decisions are made by the physician assisted by the AI software called STIMAI, and the other where trigger timing is determined by the physician alone based on clinical judgement. The AI software analyzes patient data to predict the optimal trigger day, offering options for triggering today or tomorrow, while the physician makes the final decision. The study focuses on individualized treatment to improve outcomes and scheduling. During the study, participants will undergo controlled ovarian stimulation with regular monitoring including ultrasounds. Researchers will measure the number of mature eggs retrieved about 34-36 hours after ovulation trigger, as well as other outcomes like follicle counts, length of stimulation, and number of clinic visits. The trial also tracks spontaneous ovulation and the distribution of retrieval procedures throughout the week. Participation will last through the stimulation cycle until egg retrieval, with assessments of both clinical results and process efficiency.

Age: 18Years - 42YearsFEMALEPhase Not Applicable
5 locations
C

Actively Recruiting

Researchers are studying breast cancer patients who have a positive sentinel lymph node after receiving neoadjuvant systemic treatment. The trial evaluates whether axillary radiotherapy ART reduces the risk of lymphedema compared to axillary lymph node dissection ALND in these patients. The study also examines recurrence and overall survival rates, as well as quality of life. This is a prospective, randomized, open-label, parallel group, multicenter study involving approximately 820 patients over 5 years. Participants are divided into two groups one receives axillary radiotherapy without lymphadenectomy, including radiation to levels I and II axilla, level III, supraclavicular area, and possibly the internal mammary chain the other group undergoes axillary lymph node dissection plus radiotherapy to level III, supraclavicular area, and possibly the internal mammary chain. Patients are stratified by neoadjuvant treatment type chemotherapy or hormone therapy. A pilot phase with the first 200 patients has been completed, and interim analysis will be performed. During the study, participants undergo evaluations including imaging by ultrasound or MRI to assess axillary response after neoadjuvant therapy. Researchers will track disease-free survival up to 5 years, overall survival up to 5 years, and incidence of lymphedema up to 3 years after surgery. Quality of life and safety outcomes will also be monitored. The study aims to provide data on whether avoiding lymphadenectomy is a viable option for patients responding well to neoadjuvant treatment.

Age: 18Years +All GendersPhase Not Applicable
61 locations
C

Actively Recruiting

Healthy Volunteer

Researchers are comparing changes in soft tissue volume and patient-reported outcomes around dental implants using three different graft materials a sub-epithelial connective tissue graft SCTG from the palate, porcine collagen matrix CM, and porcine acellular dermal matrix PADM. This phase 4 randomized clinical trial aims to evaluate volume gain and stability at 3 and 15 months after implant placement. The study involves four groups one receiving implant placement and prosthetic tooth rehabilitation alone, and three groups receiving implant placement plus soft tissue augmentation with either SCTG, CM, or PADM at the implant site, followed by prosthetic rehabilitation. SCTG grafts are harvested from the palate and trimmed to specific dimensions, while CM and PADM grafts are similarly trimmed and secured at the recipient site. Implant placement includes making a crestal incision and preparing the bone to place a tapered implant with a healing abutment. Participants will undergo assessments including soft tissue volume gain at 3 months and volume stability at 15 months. Additional measures include plaque index, bleeding on probing, probing depth, keratinized tissue width, phenotype evaluation at baseline, 12 weeks, and 15 months, as well as patient-reported outcomes shortly after surgery. Pink Esthetic Score will be evaluated around 16 months after crown placement. Safety and progress will be monitored throughout the study with a total participation period extending beyond 15 months.

Age: 18Years +All GendersPhase 4
1 location
C

Actively Recruiting

Researchers are evaluating the clinical performance of a 3D-printed hybrid resin called VarseoSmile TriniQ for indirect restorations in endodontically treated molars, comparing it with a traditional CADCAM composite block named Cerasmart. This study also compares two adhesive luting methods using a preheated microhybrid composite resin Enamel Plus HRi and a resin cement RelyX Universal. The trial aims to provide evidence on the effectiveness of these new materials and cementation techniques in dental restorations. Participants will be randomly assigned to one of four groups based on the combination of restorative material and luting protocol. Restorations are created through a digital workflow involving intraoral scanning, CAD design, and either 3D printing or milling. Adhesive cementation is done under rubber dam isolation following standardized clinical procedures. The study includes baseline and follow-up evaluations at 3, 6, and 12 months, with annual assessments afterward. During the study, participants will have clinical check-ups to assess restoration success using modified United States Public Health Service criteria. Researchers will evaluate factors such as marginal adaptation, contact stability, color stability, wear, fractures, secondary caries, and patient comfort. Follow-ups continue annually to monitor restoration survival. The total duration of involvement depends on each participants follow-up schedule, with detailed clinical and patient-reported outcomes collected throughout.

Age: 18Years +All GendersPhase Not Applicable
1 location
C

Actively Recruiting

Researchers are collecting detailed information about patients with venous thromboembolism VTE to improve understanding of this condition, especially in groups often excluded from clinical trials such as pregnant women, elderly patients, and those with severe health issues. This observational registry aims to provide data that can help reduce death rates, recurrences of blood clots, bleeding problems, and arterial events related to VTE. This study gathers clinical details about each patient, including other health conditions, and tracks the type, dose, duration, and results of antithrombotic treatments over the first three months. The registry is accessible online to assist doctors in managing complex cases by comparing patient profiles and identifying those at higher risk of complications. Participants clinical status and treatment outcomes are recorded, focusing on recurrence of VTE, bleeding events, and mortality over a three-year period. The information supports the creation of predictive scores to help healthcare providers identify patients at higher risk. The study started in 2001 and plans to continue until 2027, with ongoing data collection and follow-up.

All AgesAll Genders
305 locations

1-10 of 26

1